Fractyl Health grants 1,036,800 options to CFO

Fractyl Health reported a new stock option grant to its Chief Financial Officer, Lara Smith Weber.

Rhea-AI Filing Summary

Fractyl Health reported a new stock option grant to its Chief Financial Officer, Lara Smith Weber. On January 12, 2026, she was awarded a stock option covering 1,036,800 shares of common stock with an exercise price of $2 per share.

The option vests over time: 25% of the shares become exercisable on January 12, 2027, and the remaining 75% vest in 36 equal monthly installments after that date, contingent on her continued service with the company. Following this grant, she directly beneficially owns 1,036,800 derivative securities in the form of stock options.

Insider Trade Summary

Grant/Award: 1,036,800 shares

Grant/Award 1 txn

Insider Smith Weber Lara

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	1,036,800	$0.00	$0.00

Holdings After Transaction: Stock Option — 1,036,800 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 12, 2027, with the remaining 75% of the underlying shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Company as of each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Fractyl Health (GUTS) disclose in this Form 4?

The company disclosed that its Chief Financial Officer, Lara Smith Weber, received a stock option grant for 1,036,800 shares of Fractyl Health common stock on January 12, 2026.

What are the key terms of the Fractyl Health CFO stock option grant?

The CFO received a stock option for 1,036,800 shares of common stock with an exercise price of $2 per share, reported as acquired at a price of $0 for Form 4 purposes.

How do the Fractyl Health CFO’s options vest according to the filing?

The filing states that 25% of the option shares vest on January 12, 2027, and the remaining 75% vest in 36 equal monthly installments thereafter, subject to her continuous service.

How many derivative securities does the Fractyl Health CFO own after this transaction?

After the reported grant, Lara Smith Weber beneficially owns 1,036,800 derivative securities in the form of stock options, held directly.

What role does the reporting person hold at Fractyl Health (GUTS)?

The reporting person, Lara Smith Weber, serves as Chief Financial Officer of Fractyl Health, Inc.

Is this Fractyl Health Form 4 filing for non-derivative or derivative securities?

This Form 4 reports a transaction in derivative securities, specifically a stock option covering shares of Fractyl Health common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Weber Lara

(Last) (First) (Middle)

3 VAN DE GRAAFF DRIVE SUITE 200

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FRACTYL HEALTH, INC. [ GUTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2	01/12/2026		A		1,036,800		(1)	01/11/2036	Common Stock	1,036,800	$0	1,036,800	D

Explanation of Responses:

1. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 12, 2027, with the remaining 75% of the underlying shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Company as of each such vesting date.

	/s/ Sarah Toomey, Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.